Skip to main content

Table 4 Risk predictors of OS in the univariate and multivariate analyses

From: Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis

Variable Overall survival
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age (≥55 years old vs < 55 years old) 1.247 (0.673–2.310) 0.483   
AFPa (≥400ng/ml vs < 400 ng/ml) 1.858 (1.014–3.404) 0.045* 1.940 (1.008–3.735) 0.047*
Ascites (Have vs None) 2.15 (1.171–3.948) 0.014*   0.067
ECOG PSb (0–1 vs. 2) 2.414 (1.230–4.740) 0.008* 2.574 (1.278–5.185) 0.008*
Child-Pugh grade (A vs B) 2.114 (1.061–4.214) 0.033* 2.913 (1.385–6.123) 0.005*
Arterioportal fistula (Have vs None) 1.036 (0.555–1.931) 0.912   
Hemihepatic HCCc (Yes vs. No) 0.454 (0.247–0.835) 0.011* 0.517 (0.269–0.992) 0.047*
HCCc diameter (>10cm vs. ≤ 10 cm) 1.454 (0.802–2.636) 0.218   
Number of tumors (Single vs. Multiple) 0.327 (0.100–1.260) 0.065   
Distant metastasis (Yes vs. No) 1.829 (0.955–3.502) 0.069   
Hepatic vein tumor thrombosis (Yes vs. No) 1.844 (0.850–4.003) 0.122   
Cavernous transformation collateral (Yes vs. No) 0.703 (0.387–1.275) 0.246   
PVTTd type (III vs. IV) 0.801 (0.371–1.731) 0.573   
  1. *P < 0.05
  2. aAFP alpha fetoprotein
  3. bECOG PS Cooperative Oncology Group performance status
  4. cHCC hepatocellular carcinoma
  5. dPVTT portal vein tumor thrombosis